Drugs / BOS172722
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03328494 | Oct 2017 → Mar 2021 | high grade malignant neoplasm | Boston Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOS172722 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03328494 ↗ |
| Action | Inhibit | “a Monopolar Spindle 1 Kinase Inhibitor” NCT03328494 ↗ |
| Modality | Small molecule | — CHEMBL3924132 ↗ |
| Route | Oral | “oral BOS172722” NCT03328494 ↗ |